Cytogen, Inc.

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 07/05/2024 am IST			5-day change	1st Jan Change
11,600 ^KRW	-4.13%		+0.09%	-14.20%

20/03	Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI
18/03	Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI

Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited

December 28, 2023

On December 28, 2023, Cytogen, Inc. closed the transaction. The company received KRW 15,500,000,000 for series 5 bonds in its second and final tranche closing.

Latest news about Cytogen, Inc.

Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	20/03	CI
Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	18/03	CI
Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited	28/12	CI
Cytogen, Inc. announced that it expects to receive KRW 99.999821616 billion in funding from Candx Holdings Limited	28/12	CI
Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion	19/12	CI
Cytogen, Inc. announces tranche update	27/23/27	CI
Cytogen Raising KRW10 Billion to Finance Operations	27/23/27	MT
Cytogen, Inc. announced that it expects to receive KRW 69.99999 billion in funding from Excelsior Capital Korea Limited	26/23/26	CI
Cytogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Cytogen, Inc.(KOSDAQ:A217330) added to S&P Global BMI Index	20/21/20	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	21/21/21	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	21/21/21	CI
Cytogen, Inc. announced that it has received KRW 30 billion in funding	20/21/20	CI
Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding	17/21/17	CI
TSD Life Sciences Co.,Ltd. announced that it expects to receive KRW 2.9999853 billion in funding from Cytogen, Inc.	17/21/17	CI
Cytogen, Inc. announced that it has received KRW 10 billion in funding	25/20/25	CI
Cytogen, Inc. announced that it expects to receive KRW 10 billion in funding	04/20/04	CI
Well Marker Bio Co., Ltd. announced that it has received KRW 18 billion in funding from a group of investors	08/19/08	CI
Cytogen, Inc. has completed an IPO in the amount of KRW 20.4 billion.	21/18/21	CI
Cytogen, Inc. has filed an IPO.	20/18/20	CI
Cytogen, Inc. has withdrawn its IPO.	19/18/19	CI
Cytogen, Inc. has filed an IPO.	08/15/08	CI

Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
CYTOGEN, INC.	-14.20%	191M
EXACT SCIENCES CORPORATION	-17.44%	11.29B
IOVANCE BIOTHERAPEUTICS, INC.	+65.99%	3.91B
GUARDANT HEALTH, INC.	-29.57%	2.29B
BGI GENOMICS CO., LTD.	-11.81%	2.23B
VERACYTE, INC.	-27.26%	1.61B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+34.89%	1.19B
SEEGENE, INC.	-3.28%	752M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-30.51%	458M
CURIOX BIOSYSTEMS CO., LTD	+13.72%	338M

Bio Diagnostics & Testing

Cytogen, Inc.

Equities

A217330

KR7217330000

Biotechnology & Medical Research

Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited

Latest news about Cytogen, Inc.

Chart Cytogen, Inc.

Company Profile

Income Statement Evolution

Sector Bio Diagnostics & Testing